Equities analysts predict that XOMA Corporation (NASDAQ:XOMA) will announce earnings of ($0.50) per share for the current quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.57). XOMA posted earnings of ($2.89) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 82.7%. The firm is expected to report its next quarterly earnings results on Thursday, March 15th.
According to Zacks, analysts expect that XOMA will report full-year earnings of ($0.94) per share for the current financial year, with EPS estimates ranging from ($2.65) to $0.28. For the next year, analysts anticipate that the business will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.82) to ($0.25). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow XOMA.
Several research analysts recently weighed in on XOMA shares. Wedbush upgraded shares of XOMA from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $9.00 to $19.00 in a research report on Tuesday, September 5th. Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. Finally, HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of XOMA in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $30.00.
In other XOMA news, CEO James R. Neal sold 46,296 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.24, for a total transaction of $1,307,399.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas M. Burns sold 22,222 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.69, for a total transaction of $637,549.18. Following the sale, the senior vice president now owns 13,538 shares of the company’s stock, valued at approximately $388,405.22. The disclosure for this sale can be found here. Insiders have sold a total of 87,069 shares of company stock valued at $2,517,993 in the last quarter. Corporate insiders own 3.02% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. OxFORD Asset Management LLP bought a new stake in shares of XOMA during the 3rd quarter valued at $543,000. EAM Investors LLC bought a new stake in shares of XOMA in the 3rd quarter valued at $835,000. Finally, California Public Employees Retirement System increased its position in shares of XOMA by 95.5% in the 1st quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 10,640 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.
XOMA (NASDAQ XOMA) traded up $0.37 during mid-day trading on Friday, reaching $32.87. 250,638 shares of the company traded hands, compared to its average volume of 152,835. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 3.45. XOMA has a 1 year low of $3.96 and a 1 year high of $34.18.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.